Mar 4, 2026 07:54AM
Feb 26, 2026 07:31AM
Feb 26, 2026 07:30AM
Feb 23, 2026 04:15PM
Feb 23, 2026 09:36AM
Feb 23, 2026 07:01AM
Feb 23, 2026 07:00AM ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
Feb 20, 2026 08:30AM
Feb 20, 2026 08:30AM
Feb 19, 2026 09:02AM
Feb 19, 2026 09:00AM
Feb 18, 2026 09:01AM
Feb 18, 2026 09:00AM
Feb 17, 2026 06:09AM ImmunityBio discusses drug approvals with Saudi regulators
Feb 17, 2026 06:07AM
Feb 2, 2026 07:00AM
Feb 2, 2026 07:00AM
Feb 2, 2026 07:00AM
Jan 26, 2026 06:49AM
Jan 23, 2026 07:00AM
Jan 23, 2026 07:00AM ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Jan 22, 2026 01:17PM
Jan 20, 2026 07:44AM
Jan 20, 2026 04:00AM
Jan 16, 2026 07:00AM
Jan 16, 2026 07:00AM
Jan 16, 2026 07:00AM
Jan 16, 2026 07:00AM ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
Jan 15, 2026 08:32AM
Jan 15, 2026 08:30AM
Jan 14, 2026 10:39AM
Jan 14, 2026 08:30AM
Jan 14, 2026 08:30AM
Jan 14, 2026 08:30AM
Jan 13, 2026 08:30AM ImmunityBio reports positive lung cancer trial results for ANKTIVA
Jan 13, 2026 08:30AM
Jan 12, 2026 08:30AM
Dec 29, 2025 09:00AM
Dec 21, 2025 04:00AM
Dec 16, 2025 09:01AM
Dec 16, 2025 09:00AM
Dec 12, 2025 06:10AM ImmunityBio gets european drug agency nod for bladder cancer treatment
Dec 12, 2025 06:10AM
Nov 13, 2025 09:00AM
Nov 4, 2025 10:12PM
Sep 10, 2025 07:30AM
Sep 8, 2025 08:30AM
Sep 8, 2025 08:30AM
Aug 26, 2025 08:31AM ImmunityBio reports early trial results in brain cancer treatment
Aug 26, 2025 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All